Pablo Miguel
Barreiro Garcia
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Marqués de Valdecilla (8)
2023
-
Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions
Journal of Clinical Virology, Vol. 167
2017
-
HIV type 2 epidemic in Spain: Challenges and missing opportunities
AIDS, Vol. 31, Núm. 10, pp. 1353-1364
2012
-
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial
Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968
2008
-
Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin
Journal of Viral Hepatitis, Vol. 15, Núm. 5, pp. 363-369
2007
-
Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients
Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391
-
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476
-
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial
AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982
2005
-
Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C
Antiviral Therapy, Vol. 10, Núm. 5, pp. 657-662